Alzheimer’s drug approval spotlights blood tests
SummaryIn the wake of the controversial U.S. regulatory approval of the Alzheimer's drug aducanumab, physicians expect many patients with memory problems will want to know whether they are eligible. But a definitive diagnosis is expensive…